{
    "organizations": [],
    "uuid": "ceb4909aa1ce97eb033c892605c74793a1f72bb8",
    "author": "",
    "url": "https://www.reuters.com/article/idUSL8N1Q90PL",
    "ord_in_thread": 0,
    "title": "BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 19 (Reuters) - Galapagos:\n* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS\n* MOR106 SHOWED FIRST SIGNS OF ACTIVITY AND DURABLE * RESPONSES * 83% OF PATIENTS AT HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4\n* POOLED DATA ACROSS DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106\n* PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018\nSource text: bit.ly/2EDNALm\nFurther company coverage:, (Gdynia Newsroom)\n ",
    "published": "2018-02-19T09:01:00.000+02:00",
    "crawled": "2018-02-19T09:13:22.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "galapagos",
        "galapagos",
        "morphosys",
        "announced",
        "saturday",
        "mor106",
        "generally",
        "well",
        "tolerated",
        "atopic",
        "dermatitis",
        "ad",
        "patient",
        "mor106",
        "showed",
        "first",
        "sign",
        "activity",
        "durable",
        "response",
        "patient",
        "highest",
        "dose",
        "reached",
        "least",
        "improvement",
        "per",
        "atopic",
        "dermatitis",
        "area",
        "severity",
        "index",
        "week",
        "pooled",
        "data",
        "across",
        "dose",
        "cohort",
        "showed",
        "improvement",
        "ad",
        "symptom",
        "week",
        "compared",
        "baseline",
        "patient",
        "treated",
        "mor106",
        "phase",
        "development",
        "mor106",
        "planned",
        "initiated",
        "first",
        "half",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}